Overview

Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:
0

Participant gender:
All

Summary

Atypical presentations in epilepsy may include confusion status, acute maniac or delirious condition, loss of cognitive ability such as speech, interaction skills, or other praxis. Current diagnosis of epilepsy did not address on definition of seizure. The new insights of seizure semiology and their treatment response, suggest the screen tool and diagnostic criteria of epilepsy can be revised. In this study, we have two aims. The first aim is to develop a screening questionnaire by adding new semiology of epilepsy, including abnormality in psychiatry, cognition, and sleep, and to test its accuracy. The second aim is to evaluate the benefits in cognition of anti-epileptic drug intervention in participants with positive screening results.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Lamotrigine
Levetiracetam
Zonisamide

Criteria

Inclusion Criteria:

1. Age equal or more than 20-year-old 2a. Patients already diagnosed of epilepsy 2b.
Non-epileptic patients from outpatient and inpatient settings of National Taiwan University
Hospital (NTUH) and National Taiwan University Hospital Yunlin Branch (NTUHYL) 2c.
Community health people

Exclusion Criteria:

1. Participants with cognitive decline (Clinical dementia rating > 1) and could not
answer the questionnaire reliably. However, participants will be recruited if their
caregivers are fully aware of their recent condition and will help to complete the
questionnaire.

2. Pregnancy or breast-feeding

3. Having adverse effect to all the anti-epileptic drug used in the study